Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods for refolding proteins containing free cysteine residues

a technology of free cysteine residues and proteins, applied in the field of proteins making, can solve the problems of limiting the possible disulfide rearrangements involving free cysteine residues, and achieve the effect of reducing glutathione and enhancing the yield of properly folded proteins

Inactive Publication Date: 2009-10-29
BOLDER BIOTECH
View PDF9 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach significantly increases the yield of properly folded, biologically active proteins, enhancing their stability and solubility, and allows for the production of homogeneous, long-acting recombinant proteins through PEGylation.

Problems solved by technology

Although not wishing to be bound by any particular theory, the inventors postulate that the cysteine blocking agent forms a mixed disulfide with the free cysteine residue in the protein, thus limiting possible disulfide rearrangements that could occur involving the free cysteine residue.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Refolding of the Growth Hormone Mutein T3C

[0061]Methods for expressing, purifying and determining the in vitro and in vivo biological activity of recombinant human Growth Hormone (hGH) and hGH cysteine muteins are described in PCT / US98 / 14497 and PCT / US / 00 / 00931. Methods for constructing cysteine muteins of hGH also are described in PCT / US98 / 14497 and PCT / US / 00 / 00931. One preferred method for expressing hGH in E. coli is to secrete the protein into the periplasm using the STII leader sequence. Secreted hGH is soluble and can be purified by column chromatography as described in PCT / US00 / 00931. Certain cysteine muteins of hGH remain insoluble when secreted into the E. coli periplasm using the STII leader sequence. Procedures for refolding insoluble, secreted hGH proteins have not been described previously. The following protocols were developed to refold insoluble hGH cysteine muteins into a biologically active form.

[0062]The insoluble GH T3C mutein (threonine at position 3 changed to ...

example 2

Comparison of Reducing Agents Used to Refold the Growth Hormone T3C Mutein

[0063]Cultures (200 mL) of an E. coli strain expressing the T3C mutein were grown and T3C expressed as described in PCT / US00 / 00931. Insoluble T3C was isolated by lysing the cells with detergent / lysozyme treatment of the cells as described in Examples 5 and 14. This material was suspended in 20 mL of 8 M urea, 20 mM Tris pH 9 and aliquoted into 3 tubes. No reducing agent was added to the first tube (“Refold A”), 5 mM DTT was added to the second tube (“Refold B”) and 20 mM cysteine was added to the third tube (“Refold C”). After one hour of mixing at room temperature, the solubilizations were diluted into 30 mL of 10% glycerol, 20 mM Tris, pH 8. The refolds were held at 4° C. overnight. The next day, the refolds were clarified by centrifugation and loaded onto 5 mL Q-Sepharose Hi Trap columns as described in PCT / US00 / 00931. Recovered fractions were analyzed by non-reducing SDS-PAGE. The T3C protein recovered fro...

example 3

General Methods for PEGylation and Purifying PEGylated Forms of Proteins Containing Free Cysteine Residues

[0071]Proteins containing free cysteine residues can be PEGylated using a variety of cysteine-reactive PEG-maleimide (or PEG-vinylsulfone) reagents that are commercially available. The recombinant proteins are generally partially reduced with dithiothreitol (DTT), Tris(2-carboxyethyl) phosphine-HCl (TCEP) or some other reducing agent in order to achieve optimal PEGylation of the free cysteine. The free cysteine is relatively unreactive to cysteine-reactive PEGs unless this partial reduction step is performed. The amount of reducing agent required to partially reduce each mutein can be determined empirically, using a range of reducing agent concentrations at different pHs and temperatures. Reducing agent concentrations typically vary from 0.5 equal molar to 10-fold molar excess. Preferred temperatures are 4° C. to 37° C. The pH can range from 6.5 to 9.0 but is preferrably 7.5 to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
apparent molecular weightaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. patent application Ser. No. 10 / 276,358, filed Apr. 10, 2003, now U.S. Pat. No. 7,306,931, which is a national stage application under 35 U.S.C. § 371 of PCT Application No. PCT / US01 / 16088, filed May 16, 2001, which claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Ser. No. 60 / 204,617, filed May 16, 2000. The entire disclosure of each of the above-identified applications is incorporated herein by reference.STATEMENT OF GOVERNMENT INTERESTS[0002]This invention was made with government support under Grant Nos. 1 R43 CA086577, 2R44 CA086577, 1R43 CA090003, 1R43CA099217, 2R44 CA099217, 1R43 AR051609, 2R44 AR051609, each awarded by the National Institutes of Health, and under Grant No. DAMD17-00-1-01-58, awarded by the Department of the Army. The government has certain rights in the invention.REFERENCE TO A SEQUENCE LISTING[0003]This application contains a Sequence L...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12P21/00C07K5/00C12N15/09C07K1/02C07K1/113C07K14/00C07K14/505C07K14/515C07K14/52C07K14/535C07K14/56C07K14/61C07K14/78C12P21/02
CPCA61K47/48215C07K1/1133C07K14/505C07K14/515C07K14/78C07K14/535C07K14/56C07K14/61C07K14/52A61K47/60A61P5/00
Inventor ROSENDAHL, MARY S.COX, GEORGE N.DOHERTY, DANIEL H.
Owner BOLDER BIOTECH